top of page
Out Team
Our Research
STARLIGHT Initiative
Project PRESCIENT
PMAC Catalog

Welcome!

The Cancer Discovery Hub (CDH) is a one-stop pan-omics diagnostic and research core laboratory housed at the National Cancer Centre Singapore. We specialise in state-of-the-art research-grade technologies and provide expert support to investigators on all cancer related projects.

Home: Welcome

Latest news

Key events and achievements

  • 10 April 2023 : Poster Presentations + Scholar-in-Training Award, AACR Annual Meeting, Florida, USA (Jing Yi Lee, Tun Kiat Ko)

  • 02 April 2024 : Collaborative research agreement with Illumina

  • 01 Nov 2023: Poster Presentation, CTOS Annual Meeting, Dublin (Elizabeth Lee)​​

  • 15 Sep 2023 : MOU and RCA signed with Agilent Technologies, BioSyngen, BGI Research and MGI Tech

  • 14 June 2023 : Poster Presentation, ICML Lugano, Switzerland

  • 14 April 2023 : Poster Presentation, AACR Annual Meeting, Florida, USA (Bavani Kannan)​​

  • 20 Mar 2023 : ESMO Merit Award, ESMO Sarcoma and Rare Cancers Congress, Lugano, Switzerland

  • 18 Mar 2023 : Co-organizer, Singapore Lymphoma Scientific Symposium 2023

  • 12 Dec 2022 : Oral abstract, ASH Annual Meeting, New Orleans, USA​​

  • 09 Dec 2022 : Invited presentation, Stem Cell Society Singapore (SCSS) Symposium (Nimmi Baby)

  • 17 Nov 2022 : Oral paper, CTOS Annual Meeting, Vancouver, Canada (Jing Yi Lee)

  • 19 Aug 2022 : Invited speech, 6th International BRCA Forum, Singapore​​

  • 19 Aug 2022 : Collaborative research agreement with Scinnohub Pharmaceutical

  • 19 Aug 2022 : Collaborative research agreement with MGI Tech

  • 04 Aug 2022 : Collaborative research agreement with Twist Bioscience

  • 16 Jun 2022 : Best Oral Presentation, International Congress of the Asian Oncology Society (AOS 2022), South Korea (Tun Kiat Ko)

  • 12 Apr 2022 : Invited Oral Presentation at Major Symposium, AACR Annual Meeting, New Orleans, US

  • 22 Feb 2022 : Publication on circulating tumor DNA mutations in progressive gastrointestinal stromal tumors, Frontiers in Oncology

  • 17 Feb 2022 : Travel Award for Poster abstract at Japanese Society of Medical Oncology Annual Meeting, Japan (Elizabeth Lee)​​

  • 12 Jan 2022 : Commercial launch of the UNITED NGS Assay (Lucence) for Asian prevalent cancers at the NCCS

  • 21 Oct 2021 : Collaborative research agreement with STEMCELL Technologies

  • 01 Sep 2021 : Collaborative research agreement with SymBio Pharmaceuticals on EBV-positive lymphomas

  • 01 Sep 2021 : Official launch of Cancer Discovery Hub!

Home: Services

Start a project consultation with us

Featured Publications

Scientific publications supported by the Cancer Discovery Hub

Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies
Gut. 2023

Nov, 2023

Objectives: Cholangiocarcinoma (CCA) is a heterogeneous malignancy with high mortality and dismal prognosis, and an urgent clinical need for new therapies. Knowledge of the CCA epigenome is largely limited to aberrant DNA methylation. Dysregulation of enhancer activities has been identified to affect carcinogenesis and leveraged for new therapies but is uninvestigated in CCA. Our aim is to identify potential therapeutic targets in different subtypes of CCA through enhancer profiling.

Design: Integrative multiomics enhancer activity profiling of diverse CCA was performed. A panel of diverse CCA cell lines, patient-derived and cell line-derived xenografts were used to study identified enriched pathways and vulnerabilities. NanoString, multiplex immunohistochemistry staining and single-cell spatial transcriptomics were used to explore the immunogenicity of diverse CCA.

Results: We identified three distinct groups, associated with different etiologies and unique pathways. Drug inhibitors of identified pathways reduced tumour growth in in vitro and in vivo models. The first group (ESTRO), with mostly fluke-positive CCAs, displayed activation in estrogen signalling and were sensitive to MTOR inhibitors. Another group (OXPHO), with mostly BAP1 and IDH-mutant CCAs, displayed activated oxidative phosphorylation pathways, and were sensitive to oxidative phosphorylation inhibitors. Immune-related pathways were activated in the final group (IMMUN), made up of an immunogenic CCA subtype and CCA with aristolochic acid (AA) mutational signatures. Intratumour differences in AA mutation load were correlated to intratumour variation of different immune cell populations.

Conclusion: Our study elucidates the mechanisms underlying enhancer dysregulation and deepens understanding of different tumourigenesis processes in distinct CCA subtypes, with potential significant therapeutics and clinical benefits.

Contact us

  • LinkedIn
  • Facebook
  • Instagram

Thanks for submitting!

Home: Contact
bottom of page